Vaxcyte’s Strong Market Position and Financial Health Justify Buy Rating with $153 Target
Leerink Partners analyst David Risinger reiterated a Buy rating on Vaxcyte (PCVX – Research Report) on November 5 and set a price target ...
Arcellx Inc’s Anito-cel: Promising Efficacy and Best-in-Class Safety Profile Justify Buy Rating
Analyst John Newman from Canaccord Genuity maintained a Buy rating on Arcellx Inc (ACLX – Research Report) and keeping the price target ...